When Imaging Adds Value in Early-Stage Kidney Disease Drug Development
Time: 11:30 am
day: Day 1 Track 2 AM
Details:
- How imaging can minimize risk to your drug development program by providing early insights about efficacy or mode of action (MoA)
- Imaging can also help to predict progression and/or outcomes and thereby be used to enrich your trial population
- Treatment effects across organs that are metabolically linked to the kidney (i.e. liver, heart, etc.) can be investigated simultaneously using tailored imaging protocols
